Tag Archives: Jefferies

Gabelli & Co Call Bioverativ(BIVV) Stock A Buy With A Value Of $58, Morgan Stanley Disagrees

Bioverativ(BIVV), a drug company focused on hemophilia and other blood disorders, was spun off by Biogen(BIIB) last week. Gabelli & Co initiated Bivoerativ stock as a buy with a value of $58, citing the company’s strong balance sheet(no debt, $325 million in cash), its limited exposure to Medicare, its potential to benefit from corporate tax reform, and its… Read More »

Raise Your Glass To Leucadia’s Crimson Wine Group Spinoff

Leucadia (LUK) is one of those low key companies which has done a superb job for shareholders. The company has grown Book Value per share at an 18.5% CAGR and shareholder equity at over 19% since 1979. Not bad. No fancy homepage for this company, instead the spartan website offers up some links to the company’s SEC filings… Read More »